Form 4: Immunovant CEO Sells Shares to Cover Tax Obligations After RSU Vesting

Immunovant CEO Peter Salzmann sold 5,105 shares of common stock on January 8, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On January 8, 2025, Peter Salzmann, the CEO of Immunovant, Inc., sold 5,105 shares of Immunovant's common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting of 8,282 restricted stock units (RSUs) on January 1, 2025.
• The shares were sold at a weighted average price of $24.1, with individual transactions ranging from $23.91 to $24.60 per share.
• Following the transaction, Salzmann still beneficially owns 972,992 shares of Immunovant common stock.
• The sale was mandated by Immunovant's policy requiring tax obligations to be funded through a 'sell to cover' transaction, indicating it was not a discretionary sale by Salzmann.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The stock sale is related to tax obligations from RSU vesting, a common practice, and doesn't necessarily reflect a change in the executive's view of the company's prospects.

Industry Context

Executive stock sales are a common occurrence, particularly when RSUs vest, as executives often sell a portion of the shares to cover their tax liabilities. This is a standard practice and doesn't necessarily indicate a lack of confidence in the company.

Stakeholder Impact

• The sale may have a minor impact on shareholders due to the small volume of shares sold compared to the total outstanding shares.
• The 'sell to cover' policy ensures the company meets its tax obligations related to executive compensation.

Key Dates